<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01577082</url>
  </required_header>
  <id_info>
    <org_study_id>CCD-1005-PR-0040</org_study_id>
    <secondary_id>2010-020602-14</secondary_id>
    <nct_id>NCT01577082</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of CHF 1535 200/6µg in Not Adequately Controlled Asthmatic Patients</brief_title>
  <official_title>A 12-week, Multinational, Multicentre, Randomised, Double-blind, Double-dummy, 2-arm Parallel Group Study Comparing the Efficacy and Safety of CHF 1535 200/6µg Versus Beclomethasone Dipropionate in Adult Asthmatic Patients Not Adequately Controlled on High Dose of Inhaled Corticosteroids or on Medium Dose of Inhaled Corticosteroids Plus Long-acting β2 Agonists</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chiesi Farmaceutici S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chiesi Farmaceutici S.p.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to show the superiority of CHF 1535 (BDP/FF) pMDI over BDP HFA&#xD;
      pMDI in terms of lung function considering change from baseline to the entire treatment&#xD;
      period in average pre-dose morning PEF in adult asthmatic patients not adequately controlled&#xD;
      on high doses of ICS or on medium dose of ICS+LABA.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pre-dose morning PEF</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change from baseline to the entire treatment period in average pre-dose morning PEF</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pre-dose morning FEV1</measure>
    <time_frame>2 weeks</time_frame>
    <description>Change from baseline in pre-dose morning FEV1 every two weeks over a 12-week period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Asthma symptoms</measure>
    <time_frame>12 weeks</time_frame>
    <description>Asthma symptoms collected day and night-time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>14 weeks</time_frame>
    <description>Adverse Events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">542</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>CHF 1535 200/6µg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BDP 100µg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CHF1535 200/6 µg</intervention_name>
    <description>CHF 1535 (BDP/FF) 800/24 µg daily during 12 weeks</description>
    <arm_group_label>CHF 1535 200/6µg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BDP 100 µg</intervention_name>
    <description>Beclomethasone Dipropionate 800µg daily during 12 weeks</description>
    <arm_group_label>BDP 100µg</arm_group_label>
    <other_name>Qvar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:&#xD;
&#xD;
          -  Male or female patients aged &gt; 18 years.&#xD;
&#xD;
          -  Patients with persistent asthma not optimally controlled (GINA 2010) on high doses of&#xD;
             ICS or medium dose of ICS+LABA at a stable dose for at least 4 weeks prior to&#xD;
             screening.&#xD;
&#xD;
          -  Patients with FEV1 &gt;= 40% and &lt; 80% of predicted for the patient normal value and at&#xD;
             least 0.9 L.&#xD;
&#xD;
          -  Patients with a documented positive response to the reversibility test, defined as&#xD;
             ΔFEV1 &gt;= 12% and &gt;= 200 mL over baseline, within 30 minutes after administration of&#xD;
             400 μg of salbutamol pMDI.&#xD;
&#xD;
          -  At screening and at the end of the run-in period, patients with not adequately&#xD;
             controlled asthma according to GINA 2010 and with score at the Asthma Control&#xD;
             Questionnaire (ACQ)&gt; 0.75&#xD;
&#xD;
        Main Exclusion Criteria:&#xD;
&#xD;
          -  History of near fatal asthma or of a past hospitalisation for asthma in Intensive Care&#xD;
             Unit or of frequent exacerbations (3 or more asthma exacerbations/ year).&#xD;
&#xD;
          -  Hospitalisation, Emergency Room admission or use of systemic steroids (more than 3&#xD;
             days) for asthma exacerbation in the 4 weeks prior to screening visit and during the&#xD;
             run-in period.&#xD;
&#xD;
          -  Symptomatic infection of the lower airways in the 4 weeks before the screening visit.&#xD;
&#xD;
          -  Current or ex-smokers with total cumulative exposure equal or more than 5 pack-years&#xD;
             and /or having stopped smoking one year or less prior to screening visit.&#xD;
&#xD;
          -  Patients with a clinically significant abnormality at 12-lead ECG or presenting a QTcB&#xD;
             interval value in ECG &gt; 450 msec in males or &gt; 470 msec in females).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierluigi Paggiaro, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cardio-Thoracic and Vascular Dept, University of Pisa</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cardio-Thoracic and Vascular Dept, University of Pisa</name>
      <address>
        <city>Pisa</city>
        <zip>56124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020602-14</url>
    <description>Study Record on EU Clinical Trials Register including results</description>
  </link>
  <link>
    <url>https://www.chiesi.com/clinic/CSR_Synopsis_CCD-1005-PR-0040.pdf</url>
    <description>CSR Synopsis available in the CHIESI Clinical Study Register</description>
  </link>
  <results_reference>
    <citation>Paggiaro P, Corradi M, Latorre M, Raptis H, Muraro A, Gessner C, Siergiejko Z, Scuri M, Petruzzelli S. High strength extrafine pMDI beclometasone/formoterol (200/6 μg) is effective in asthma patients not adequately controlled on medium-high dose of inhaled corticosteroids. BMC Pulm Med. 2016 Dec 9;16(1):180.</citation>
    <PMID>27938358</PMID>
  </results_reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>April 6, 2012</study_first_submitted>
  <study_first_submitted_qc>April 12, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 13, 2012</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Adults, not adequately controlled, pre-dose morning PEF</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

